Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049356 | 1.00 | ALDH1A1 (0.66) | ALDH1A1POLBL3MBTL1GAAKMT2A | |
| SCHEMBL17049289 | 0.92 | ALDH1A1 (0.56) | ALDH1A1POLBL3MBTL1GAAKMT2A | |
| SCHEMBL25252331 | 0.88 | L3MBTL1 (0.56) | ALDH1A1POLBL3MBTL1GAAKMT2A | |
| SCHEMBL25252329 | 0.88 | L3MBTL1 (0.56) | ALDH1A1POLBL3MBTL1GAAKMT2A | |
| SCHEMBL17049339 | 0.87 | LMNA (0.53) | ALDH1A1POLBL3MBTL1GAAKMT2A | |
| SCHEMBL17049347 | 0.87 | ALDH1A1 (0.52) | ALDH1A1POLBL3MBTL1GAAKMT2A | |
| SCHEMBL17049345 | 0.87 | ALDH1A1 (0.52) | ALDH1A1POLBL3MBTL1GAAKMT2A | |
| SCHEMBL17049337 | 0.87 | LMNA (0.53) | ALDH1A1POLBL3MBTL1GAAKMT2A | |
| SCHEMBL19597541 | 0.85 | ALDH1A1 (0.70) | ALDH1A1POLBL3MBTL1GAAKMT2A | |
| SCHEMBL19597540 | 0.85 | ALDH1A1 (0.70) | ALDH1A1POLBL3MBTL1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988390-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20170267680-A1 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-09-21 | — | — | US | disclosed |
| WO-2017072341-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-04 | — | — | WO | disclosed |
| WO-2015131100-A1 | LIGAND-CONTROLLED C(SP3)-H ARYLATION AND OLEFINATION IN SYNTHESIS OF UNNATURAL CHIRAL ALPHA AMINO ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267680-A1 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | XDH, HPRT1, IMPDH1 | ALDH1A1 285/4885POLB 224/4885L3MBTL1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.